Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma

Anticancer Research

Volumn 19, Issue 6 C, 1999, Pages 5515-5521

  Samejima, Ryuichiro ^a   Kitajima, Yoshihiko ^a   Yunotani, Seiji ^a   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Chemoradiation sensitivity; Chemoradiotherapy; Cyclin D1; Esophageal squamous cell carcinoma; Immunohistochemistry; Ki 67; p53

Indexed keywords

CISPLATIN; CYCLIN D1; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; ESOPHAGOGRAPHY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYCLIN D1; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033368051     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Walsh TN, Noonan N, Hollywood D, Kelly A, Stat C, Keeling N and Hennessy TPJ: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Eng J Med 335: 462-467, 1996.
2. Vogel SB, Mendenhall WM, Sombeck MD, Marsh R and Woodward ER: Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 221: 685-695, 1995.
3. Law S, Fok M, Chow S, Chu KM and Wong J: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114: 210-217, 1997.
4. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
5. White E: Life, death, and the pursuit of apoptosis. Genes Dev 10: 1- 15, 1996.
6. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
7. Righetti SC, Torre GD, Pilotti S, Ménard S, Ottone- F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G and Zunino F: A comparative study of p53 gene mutation, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689- 693, 1996.
8. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E and Weichselbaum RR: p53 mutation dose not correlate with radio- sensitivity in 24 head and neck cancer cell lines. Cancer Res 53: 3667- 3669, 1993.
9. Raybaud-Diogéne H, Fortin A, Morency R, Roy J, Monteil RA and Têtu B: Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 15: 1030-1038, 1997.
10. Schlüter C, Duchrow M, Wohlenberg C, Becker MHG, Key G, Flad H and Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, Ubiquitous nuclear protein with nuumerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123: 513-522, 1993.
11. Sasaki K, Matsumura K, Tsuji T, Shinozaki F and Takahashi M: Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors.Cancer 62: 989-993, 1998.
12. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
13. Hochhauser D: Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drugs 8: 903-910, 1997.
14. Jiang W, Kahn SM, Tomita N, Zhang Y, Lu S and Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980-2983, 1992.
15. Naitoh H, Shibata J, Kawaguchi A, Kodama M and Hattori T: Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 146: 1161-1169, 1995.
16. Japanese Society for Esophageal Diseases. Guide lines for the clinical and pathologic studies on carcinoma of the esophagus. The 8th Edition. Tokyo, Kanehara Inc., 1992, pp 32-58.
17. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN and Hennessy TPJ: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 74: 1693- 1698, 1994.
18. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL and Wolfe WG: The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 221: 677-684, 1995.
19. Lam K-Y, Law S, Ma LT, Ong S-K and Wong J: Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: Do histological assessment and p53 overexpression predict chemo- responsiveness ? Eur J Cancer 33: 1221-1225, 1997.
20. Siddik ZH, Mims B, Lozano G and Thai G: Independent pathways p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58: 698-703, 1998.
21. Skladanowski A and Larsen AK: Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implication for gene therapy. Cancer Res 57: 818-823, 1997.
22. Cascinu S, Graziano F, Ferro ED, Staccioli MP, Ligi M, Carnevali A, Muretto P and Catalano G: Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83: 1917-1922, 1998.
23. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S and Gabbert HE: Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int. J. Cancer 84: 86-91, 1999.
24. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M and Kitajima M: Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin. Cancer Res 2: 1155-1161, 1996.
25. Warenius HM, Seabra LA and Maw P: Sensitivity to cis-diammine- dichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer 67: 224-231, 1996.
26. Kornmann M, Arber N and Korc M: Inhibition of basal and mitogen- stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352, 1998.
27. Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise- Helmericks R and Li WW: Effect of cyclin D1 overexpression on drug sensitivity in human fibrosarcoma cell line. J Natl Cancer Inst 88: 1269-1275, 1996.
28. Degregori J, Kowalik T and Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S- regulatory genes. Mol Cell Biol 15: 4215-4224, 1995.